From Betabodies and Talceptrx To China Merchant Bank
In the deal between CDMO/Avid and Oncologie all trademarks, except the Avid specific ones, have been passed on to Oncologie.
Oncologie - Trademarks
However, lets think about this for a moment. All trademarks have been abandonned by Oncologie except Betabodies (granted registry in 2014 and maintained so it is currently in 'registered' state) and TALCEPTRX which was one of the 3 names PPHM registered (together with the abandoned YUVIZO and TALRIMZA).
As an appetizer, we could have know at the time that TALCEPTRX was the PPHM preferred name. They did not file for registration in Madrid for the two others but did it for TALCEPTRX the day after TALCEPTRX was published for opposition (2016/03/01).
That Oncologie has plans for TALCEPTRX shows in the registration page of the TALCEPTRX logo. The registration was started when it was still PPHM but was extended in September 2018 (for the 4th time) when it was already Oncologie. TALCEPTRX Logo.
But here comes the thing:
ALL 3 (BETABODIES, TALCEPTRX, and TALCEPTRIX Logo) have a "change of ownership' in JUNE 2018. That is a REAL change of ownership, not an automatic change of ownership. So the change of ownership was filled for.
We know it was done on JUNE 1st 2018 because of the Madrid procedure who lists the filing date, versus the US procedure that lists the effect of non-automatic change of ownership on 13th JUNE.
So I decided to dig deeper.
On JUNE 10th 2018 we get this:
Oncology raises 80Milj$ from Nan Fung Life Sciences Series B
Nan Fung is the LEAD INVESTOR and also SEEDED Oncologie a year before.
Now say again that there is no consistent strategy behind all this.
Date Party Lead Inv Founding Round Raised
Jun 10, 2019 Oncologie Yes Series B $80M
Mar 5, 2019 Eargo Series D $52M
Feb 7, 2019 Bolt Biotherapeutics Series B $54M
Jan 4, 2019 Oculis Series B CHF15.5M
Sep 19, 2018 Galera Therapeutics Series C $70M
Jul 31, 2018 Omniome Series B $60M
Jun 7, 2018 Oncologie Seed Round $16.5M
Jan 3, 2018 SomaLogic Priv.Eqty.Round $200M
Dec 18, 2017 Aptinyx Series B $70M
Oct 19, 2017 Eargo Yes Series C $45M
Except for the 200Milj$ for Somalogic, Oncologie is second biggest investment with 96.5Milj$. Not bad for a company with a drug, bavituximab, considered a worthless failure. The ex-PPHM molecules and technologie are mentioned explicitely as the main reason of funding by Peter Bisgaard.
Jun 7, 2018
Oncologie raised $16,500,000 / Seed from CMB International Capital Corporation and 3 other investors
Jun 10, 2019
Oncologie raised $80,000,000 / Series B from Korea Investment Partners and 3 other investors
Note Peter Bisgaard is also Managing Partner of an Investment Company that serves mainly California. Somewhere i think were we may end up...but just to soon to say yet.
PRESENT
Managing Director Nan Fung Life Sciences
Managing Partner Pivotal bioVenture Partners LLC
Pivotal's Portfolio
sources:
Nan Fung Life Sciences
Peter Tuxen Bisgaard
CMB ICC (Hong Kong) wholly-owned subsidiary of China Merchants Bank (CMB)
Pivotal bioVenture Partners LLC
